Remove Branding Remove Drug Delivery Remove Genetics
article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

The production of commercial dose non-sterile products such as tablets, capsules, ointments, creams, and powders is rising due to their growing global demand, attributed to increasing demand for anti-ageing products, hereditary factors, genetic mutations, exposure to harmful radiation, and rising geriatric population.

Marketing 130
article thumbnail

Bad behaviour: why understanding human behaviour can improve outcomes

pharmaphorum

This research also shows the complex system that drives our health outcomes, including the environment, our genetics and our social circumstances. Personalisation : creating interventions based on individuals knowing their genetics, biology and psychology as well as their social and geographical environment.

Genetics 124
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83
article thumbnail

Crescita Announces Licensing Agreement for Pliaglis; in China

The Pharma Data

With years of extensive experience in the field of skin health, the Company has successively built the “Juyou” brand for skin barrier repair, now recommended by thousands of public hospitals in China ; the professional baby skincare brand “Juyou Baby”, as well as the “Dermacid” brand, just to name a few.

article thumbnail

Transitioning Between Academia and Industry: Advice from Leading Scientists That Made the Switch

XTalks

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry.